Galera Therapeutics Company Overview
Galera Therapeutics
About Galera Therapeutics
Galera Therapeutics (NASDAQ:GRTX) specializes in developing innovative treatments targeting the oxygen metabolic pathways. The company's mission revolves around crafting novel therapeutics for the treatment of cancer, focusing primarily on mitigating the side effects of radiotherapy. One of its flagship projects includes the development of drugs poised to transform the care for patients undergoing radiation therapy by reducing its harmful side effects and potentially enhancing the therapeutic outcomes. With a keen eye on advancing its pipeline to address unmet medical needs, Galera aims to lead in the oncology field by improving both the quality of life and survival rates for cancer patients worldwide.
What is Galera Therapeutics known for?
Snapshot
2012
Year founded
19
Employees
Malvern, United States
Head office
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Galera Therapeutics
- Developing avasopasem manganese (GC4419), aimed at reducing severe oral mucositis in patients undergoing radiotherapy for head and neck cancer.
- Investigating the application of avasopasem manganese for treating esophagitis in lung cancer patients receiving radiotherapy.
- Exploring broader therapeutic uses of avasopasem manganese, including its potential to mitigate radiation-induced dermatitis.
- Development of novel small molecule therapeutics aimed at transforming the treatment landscape for cancer patients facing radiation and chemotherapy-induced side effects.
equipe executiva do Galera Therapeutics
- Dr. J. Mel Sorensen M.D.CEO, President & Director